2008
Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study
Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, Zipursky RB, Perkins DO, Tohen M, Breier A, McGlashan TH. Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research 2008, 105: 1-9. PMID: 18774696, DOI: 10.1016/j.schres.2008.07.008.Peer-Reviewed Original ResearchConceptsNeuropsychological courseDouble-blind treatment studyNeuropsychological StatusPlacebo-assigned subjectsPutative prodromal stateDouble-blind trialFrank psychotic episodeEarly convertersOlanzapine treatmentNeuropsychological deficienciesFrank psychosisMedication studiesFirst episodePsychotic episodeProdromal stateHigh riskBlind trialNeuropsychological declineTreatment studiesPsychotic conditionsPsychosisLate convertersOlanzapineProdromeInitial assessment
2006
Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. American Journal Of Psychiatry 2006, 163: 790-799. PMID: 16648318, DOI: 10.1176/ajp.2006.163.5.790.Peer-Reviewed Original ResearchConceptsOlanzapine patientsPlacebo patientsProdromal symptomsPsychosis ratesDouble-blind treatment periodEfficacy of olanzapineFurther treatment researchOlanzapine Versus PlaceboOlanzapine-treated patientsDouble-blind trialPhase of illnessPositive prodromal symptomsInduced Weight GainHazard of conversionSignificant differencesNorth American clinicsSignificant treatment differencesOlanzapine groupVersus PlaceboPlacebo groupSymptom scoresEfficacy measuresWeek 8Treatment periodPatients